Wordt geladen...
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer
To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patien...
Bewaard in:
| Gepubliceerd in: | Int J Clin Exp Med |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
e-Century Publishing Corporation
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4565207/ https://ncbi.nlm.nih.gov/pubmed/26379824 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|